CytomX Therapeutics and its partner Amgen jointly decided not to continue the development of the CX-904 program, an EGFRxCD3 T-cell engager. This decision follows earlier reductions in capital allocation to the program in early 2025, based on overall pipeline priorities. The termination was disclosed in CytomX's 2024 Annual Report.
CX-904 was CytomX's first partnered T-cell engager program to enter the clinic. While the company expressed disappointment with the termination, it stated that valuable lessons were learned from the CX-904 clinical study.
CytomX remains optimistic about the potential of future masked T-cell engagers and plans to make additional progress on this modality within its partnerships. The termination reflects a strategic prioritization to focus resources on the most promising opportunities within its pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.